Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer

Nikolaos Xenidis,Nikolaos Vardakis,Ioannis Varthalitis,Stylianos Giassas,E. Kontopodis,Nikolaos Ziras,Ioannis Gioulbasanis,George Samonis,K. Kalbakis,Vassilis Georgoulias

Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer

2011

Nikolaos Xenidis
Nikolaos Vardakis
Ioannis Varthalitis
Stylianos Giassas
E. Kontopodis
Nikolaos Ziras
Ioannis Gioulbasanis
George Samonis
K. Kalbakis
Vassilis Georgoulias

Purpose To evaluate efficacy and toxicity of a combination of pegylated liposomal doxorubicin and irinotecan in patients with refractory small-cell lung cancer.

Keywords:

Cancer
Refractory
Topoisomerase
Phases of clinical research
Doxorubicin
Cancer research
Pharmacology
Lung cancer
Irinotecan
Pathology
Toxicity
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations